Wei‐Ting Hwang

Hospital of the University of Pennsylvania — United States

Medicine · Health Sciences

72h-index26.3kcitations527works9.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(82), Lung Cancer Treatments and Mutations(45), Cancer Immunotherapy and Biomarkers(44), Breast Cancer Treatment Studies(43), Bladder and Urothelial Cancer Treatments(32)

Publications525 total

Supplementary Table 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer
2025Open Access
Supplementary Figure 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer
2025Open Access
Clinical trial protocol1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer
2025Open Access
Supplementary Tables and Figures from Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy
2025Open Access
Table S7 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
2025Open Access
Table S9 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
2025Open Access
Figure S2 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
2025Open Access
Table S1 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
2025Open Access
Table S4 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
2025Open Access
Table S10 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
2025Open Access
Table S12 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
2025Open Access
Figure S1 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
2025Open Access
Table S3 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
2025Open Access
Table S5 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
2025Open Access
Table S11 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
2025· 1 citedOpen Access
Table S6 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
2025Open Access
Table S13 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
2025Open Access
Table S8 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
2025Open Access
Table S2 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
2025Open Access
Cardiovascular outcomes of patients transitioned from ibrutinib to an alternate bruton tyrosine kinase inhibitor for hypertension and/or cardiovascular adverse events
Blood·2025
page 1 of 27Next →

Frequent Co-authors

Carl H. June(14), Bruce L. Levine(11), Simon F. Lacey(10), J. Joseph Melenhorst(10), Edward A. Stadtmauer(7), Gabriela Plesa(7), Megan M. Davis(6), Adam D. Cohen(6), Lawrence J. Solin(6), Anne E. Kazak(6), Vanessa Gonzalez(5), Michael C. Milone(5), Joseph A. Fraietta(5), Irina Kulikovskaya(5), Donald L. Siegel(5), Elizabeth O. Hexner(5), Alfred L. Garfall(5), Dan T. Vogl(5), Melissa A. Alderfer(5), Anne Chew(4)